- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02268435
Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors
A Trial of Dovitinib in Combination With Imatinib in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors After Failure to Imatinib and Sunitinib
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Studietype
Fase
- Fase 1
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 19 years or older
- Histologically confirmed metastatic or unresectable GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene
- Disease control (response or stabilization for at least 6 months with first-line imatinib and failure of prior treatments for GIST, including at least both imatinib and sunitinib and/or regorafenib. However, patients with imatinib rechallenge will not be accrued.
- ECOG performance status of 0~2
- Resolution of all toxic effects of prior treatments to grade 0 or 1
- At least one evaluable or measurable lesion for phase I study
Adequate bone marrow, hepatic, renal, and other organ functions
- Neutrophil > 1,500/mm3
- Platelet > 75,000/mm3
- Hemoglobin > 8.0 g/dL
- Total bilirubin < 1.5 x upper limit of normal
- AST/ALT < 2.5 x ULN with no exceptions
- Creatinine < 1.5 x ULN
- Life expectancy > 12 weeks
- Women with reproductive potential must have a negative serum or urine pregnancy test; and men and women of reproductive potential must practice an effective method of avoiding pregnancy while receiving study drug.
- Washout period of previous TKIs or chemotherapy for more than 4 times the half life.
- No prior use of dovitinib or other inhibitors of FGFR except regorafenib
- Provision of a signed written informed consent
Exclusion Criteria:
- Women of child-bearing potential who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control. Barrier contraceptives must be used throughout the trial in both sexes.
Clinically significant cardiac disease or impaired cardiac function or clinically significant cardiac diseases, including any one of the following:
- LVEF < 45%
- Complete left bundle branch block
- Obligate use of a cardiac pacemaker
- Congenital long QT syndrome
- History or presence of ventricular tachyarrhythmia
- Presence of unstable atrial fibrillation .
- Clinically significant resting bradycardia
- Uncontrolled hypertension
- QTc > 480 msec on screening ECG
- Right bundle branch block + left anterior hemiblock
- Angina pectoris ≤ 3 months prior to starting study drug
- Acute Myocardial Infarction ≤ 3 months prior to starting study drug
- Other clinically significant heart disease
- Uncontrolled infection
- Subjects who did not tolerate previous imatinib treatment.
- Diabetes mellitus with signs of clinically significant peripheral vascular disease
- Previous pericarditis; clinically significant pleural effusion in the previous 12 months or current ascites requiring two or more interventions/month 7. Known pre-existing clinically significant disorder of the hypothalamic-pituitary axis, adrenal or thyroid glands
8. Prior acute or chronic pancreatitis of any etiology 9. Malabsorption syndrome or uncontrolled gastrointestinal toxicities with toxicity greater than NCI CTCAE grade 2 10. Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for this study 11. Treatment with any of the medications that have a potential risk of prolonging the QT interval or inducing Torsades de Points and the treatment cannot be discontinued or switched to a different medication prior to starting study drug 12. Use of ketoconazole, erythromycin, carbamazepine, phenobarbital, rifampin, phenytoin and quinidine 2 weeks prior baseline 13. Major surgery ≤ 28 days prior to starting study drug or who have not recovered from side effects of such therapy 14. Known diagnosis of HIV infection 15. History of another primary malignancy that is currently clinically significant or currently requires active intervention 16. Patients with brain metastases as assessed by radiologic imaging due to symptoms clinically suspected of brain metastases 17. Alcohol or substance abuse disorder
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Dovitinib plus Imatinib
Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
|
Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Maximal tolerated dose and recommended dose
Tijdsspanne: 3 years
|
Initially three patients will be treated at each dose level.
If one out of three patients experiences a DLT, three additional patients will be entered at that dose level.
Dose escalation will be continued until DLTs are experienced in two or more out of six patients (more than 33% of patient cohort), which will be defined as the MTD.If more than 33% of patients experience a DLT in a dose level, one doe level below will be the RD
|
3 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Disease control rate
Tijdsspanne: 3 years
|
response + stable disease evaluated with abdominal and pelvic spiral CT scan every 4 weeks for the first 8 weeks, and then every 8 weeks, using RECIST criteria v1.1
|
3 years
|
Overall response rate
Tijdsspanne: 3 years
|
response + stable disease evaluated with abdominal and pelvic spiral CT scan every 4 weeks for the first 8 weeks, and then every 8 weeks, using RECIST criteria v1.1
|
3 years
|
Number of Participants with Adverse Events as a Measure of Safety
Tijdsspanne: 3 years
|
Safety by NCI CTCAE version 4.0
|
3 years
|
Progression-free survival
Tijdsspanne: 3 years
|
response + stable disease evaluated with abdominal and pelvic spiral CT scan every 4 weeks for the first 8 weeks, and then every 8 weeks, using RECIST criteria v1.1
|
3 years
|
Overall survival (OS)
Tijdsspanne: 3 years
|
OS assessment dates will be the time point when 6 months have passed after the enrollment of the last patient
|
3 years
|
optionally, correlation of efficacy with potential biomarkers
Tijdsspanne: 3 years
|
mutational analysis of KIT exons 9, 11, 13, and 17, and PDGFRα exons 12, 14, and 18 with direct sequencing using DNA extracted from archival tissues and/or newly obtained tissues at baseline, and with BEAMing assay using ctDNA extracted from plasma at baseline and every time when follow-up CT scans are conducted; optionally circulating growth factors including but not limited to VEGF, bFGF, IL-8, PLGF, FGFR2, and FGF23, and soluble receptors including but not limited to sVEGFR1 and 2 with plasma collected at baseline and on Cycle 1 Week 4 Day 5
|
3 years
|
next generation sequencing will be performed in newly obtained tissues at baseline to find out new genetic changes after failure of previous standard TKIs
Tijdsspanne: 3 years
|
3 years
|
|
Optionally, activation of FGFR signaling will be analyzed using the reverse phase protein microarray and/or immunohistochemistry including but not limited to pFRS2 and pFGFR in archival tissues and/or newly obtained tissues at baseline
Tijdsspanne: 3 years
|
3 years
|
|
Imatinib and dovitinib plasma concentrations vs time profile, and basic pharmacokinetics parameters
Tijdsspanne: 3 years
|
PK samples will be taken at 0 hour (pre-dose) and at 1, 2, 3, 4, 6, and 8 hours (post-dose) after administration of dovitinib and imatinib on Cycle 1 Week 1 Day 1, Cycle 1 Week 1 Day 5, and Cycle 1 Week 4 Day 5
|
3 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Yoon-Koo Kang, PhD, Asan Medical Center
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het spijsverteringsstelsel
- Neoplasmata, bindweefsel en zacht weefsel
- Neoplasmata per histologisch type
- Neoplasmata
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Neoplasmata, bindweefsel
- Gastro-intestinale stromale tumoren
- Moleculaire mechanismen van farmacologische werking
- Enzymremmers
- Antineoplastische middelen
- Proteïnekinaseremmers
- Imatinib-mesylaat
Andere studie-ID-nummers
- AMC1401
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Gastro-intestinale stromale tumoren
-
Sorrento Therapeutics, Inc.IngetrokkenVaste tumor | Recidiverende vaste tumor | Refractaire tumor
-
Aadi Bioscience, Inc.WervingGeavanceerde vaste tumor | Tumor | Tumor, solideVerenigde Staten
-
Memorial Sloan Kettering Cancer CenterWervingVaste tumor | Vaste tumor, volwassen | Vaste tumor, niet gespecificeerd, volwassenVerenigde Staten
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterWervingVaste tumor | Vaste tumor, volwassen | Vaste tumor, niet gespecificeerd, volwassenVerenigde Staten, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterWervingVaste tumor | Vaste tumor, volwassen | Vaste tumor, niet gespecificeerd, volwassenVerenigde Staten, Puerto Rico
-
RemeGen Co., Ltd.VoltooidMetastatische vaste tumor | Lokaal geavanceerde vaste tumor | Inoperabele vaste tumorAustralië
-
National Health Research Institutes, TaiwanNational Cheng-Kung University HospitalWerving
-
Elpiscience Biopharma, Ltd.Shanghai Junshi Bioscience Co., Ltd.WervingNeoplasmata | Vaste tumor | Kwaadaardige tumorChina
-
The First Affiliated Hospital of Xiamen UniversityWervingVaste tumor | Tumor | Positron-emissietomografieChina
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyWervingVaste tumor, volwassen | Refractaire tumorVerenigde Staten
Klinische onderzoeken op dovitinib plus imatinib
-
Novartis PharmaceuticalsVoltooidNeoplasmata | Kanker | TumorenVerenigde Staten
-
Yonsei UniversityVoltooidSchildklierkankerKorea, republiek van
-
Abramson Cancer Center of the University of PennsylvaniaVoltooidInoperabel paraganglioom | Recidiverend feochromocytoom | Gevorderd gemetastaseerd paraganglioom | Gevorderd gemetastaseerd feochromocytoom | Recidiverend paraganglioom | Inoperabel feochromocytoomVerenigde Staten
-
Samsung Medical CenterOnbekendPlaveiselcel NSCLCKorea, republiek van
-
Novartis PharmaceuticalsVoltooidUitgezaaide borstkankerVerenigde Staten, Canada, Finland, Frankrijk, Italië, Spanje, Taiwan, Verenigd Koninkrijk
-
M.D. Anderson Cancer CenterNovartisBeëindigd
-
Korean Cancer Study GroupVoltooidHormoon refractaire prostaatkankerKorea, republiek van
-
Novartis PharmaceuticalsVoltooidTumor Pathway-activeringen geremd door DovitinibVerenigde Staten
-
Novartis PharmaceuticalsVoltooidEndometriumkanker | VEGF | Solide tumoren en gevorderde endometriumkanker | Tweedelijns behandelingItalië, Verenigd Koninkrijk, Spanje, Brazilië, Verenigde Staten, Korea, republiek van, Nieuw-Zeeland
-
Auckland District Health BoardNovartis; University of Auckland, New Zealand; IGENZ, Ltd., AucklandOnbekendHeldercellig niercelcarcinoomNieuw-Zeeland